Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Frébourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E. Bruera G, et al. Among authors: lamy a. BMC Med. 2012 Nov 8;10:135. doi: 10.1186/1741-7015-10-135. BMC Med. 2012. PMID: 23136868 Free PMC article.
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.
Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T. Di Fiore F, et al. Among authors: lamy a. Br J Cancer. 2007 Apr 23;96(8):1166-9. doi: 10.1038/sj.bjc.6603685. Epub 2007 Mar 20. Br J Cancer. 2007. PMID: 17375050 Free PMC article.
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F. Bibeau F, et al. Among authors: lamy a. J Clin Oncol. 2009 Mar 1;27(7):1122-9. doi: 10.1200/JCO.2008.18.0463. Epub 2009 Jan 21. J Clin Oncol. 2009. PMID: 19164213
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.
Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, Blanchard F, Tougeron D, Ychou M, Boissière F, Le Pessot F, Sabourin JC, Tuech JJ, Michel P, Frebourg T. Oden-Gangloff A, et al. Among authors: lamy a. Br J Cancer. 2009 Apr 21;100(8):1330-5. doi: 10.1038/sj.bjc.6605008. Br J Cancer. 2009. PMID: 19367287 Free PMC article.
Genetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer.
Sarafan-Vasseur N, Sefrioui D, Tougeron D, Lamy A, Blanchard F, Le Pessot F, Di Fiore F, Michel P, Bézieau S, Latouche JB, Frebourg T, Sesboüé R. Sarafan-Vasseur N, et al. Among authors: lamy a. BMC Cancer. 2013 Apr 8;13:183. doi: 10.1186/1471-2407-13-183. BMC Cancer. 2013. PMID: 23565769 Free PMC article.
Gestational choriocarcinoma associated with a germline TP53 mutation.
Brehin AC, Patrier-Sallebert S, Bougeard G, Side-Pfennig G, Llamas Gutierrez F, Lamy A, Colasse E, Kandel-Aznar C, Delnatte C, Vuillemin E, Sadot-Lebouvier S, Odent S, Sabourin JC, Golfier F, Frebourg T. Brehin AC, et al. Among authors: lamy a. Fam Cancer. 2018 Jan;17(1):113-117. doi: 10.1007/s10689-017-9996-7. Fam Cancer. 2018. PMID: 28477316
294 results